BIOHIT HealthCare to host symposium on gastric cancer at BSG LIVE’24

Kyver­na Ther­a­peu­tics start­ed its first day as a pub­lic biotech on a strong note, with its shares $KYTX ris­ing more than 50% Thurs­day af­ter­noon af­ter

Catal­ent’s lat­est SEC fil­ings added de­tail to the mag­ni­tude of the man­u­fac­tur­er’s 2023 rev­enue down­turn, head­count re­duc­tions and the im­pact of re­duced de­mand on its